Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.58M Sell
27,879
-75
-0.3% -$8.78K 1.45% 33
2026
Q1
$3.36M Sell
27,954
-138
-0.5% -$15.9K 1.56% 27
2025
Q4
$2.96M Sell
28,092
-10,027
-26% -$941K 1.36% 34
2025
Q3
$3.2M Buy
38,119
+10,136
+36% +$835K 1.48% 30
2025
Q2
$2.22M Sell
27,983
-21
-0.1% -$1.67K 1.07% 46
2025
Q1
$2.51M Buy
28,004
+5,951
+27% +$556K 1.29% 45
2024
Q4
$2.19M Sell
22,053
-135
-0.6% -$13.9K 1.26% 42
2024
Q3
$2.52M Sell
22,188
-855
-4% -$102K 1.63% 35
2024
Q2
$2.85M Sell
23,043
-47
-0.2% -$6.05K 1.97% 22
2024
Q1
$3.05M Sell
23,090
-272
-1% -$33.5K 2.06% 13
2023
Q4
$2.55M Buy
+23,362
New +$2.43M 1.86% 18

Other funds holding MRK

Lynx Capital Group's MRK Position: Q2 2026 in Review

Lynx Capital Group reduced its Merck (MRK) stake by 0.27% in Q2 2026, selling an estimated $8.78K and leaving 27,879 shares worth $3.58M. The position accounts for 1.45% of the portfolio, ranked #33.

Lynx Capital Group first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. 3,688 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Lynx Capital Group held 27,879 shares of Merck worth $3.58M as of Q2 2026.
  • Lynx Capital Group sold 75 Merck shares in Q2 2026, an estimated $8.78K.
  • Merck made up 1.45% of Lynx Capital Group's portfolio in Q2 2026, its #33 holding.
  • Lynx Capital Group first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • 3,688 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Lynx Capital Group's 13F filing for Q2 2026, filed 12 Aug 2026.